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Rapid and efficient generation of neural
progenitors from adult bone marrow
stromal cells by hypoxic preconditioning
Kwan-Long Mung1,2†, Yat-Ping Tsui2†, Evelyn Wing-Yin Tai1,2, Ying-Shing Chan2, Daisy Kwok-Yan Shum2
and Graham Ka-Hon Shea1,3*
Abstract
Background: Bone marrow stromal cells (BMSCs) are attractive as a source of neural progenitors for ex vivo generation
of neurons and glia. Limited numbers of this subpopulation, however, hinder translation into autologous cell-based
therapy. Here, we demonstrate rapid and efficient conditioning with hypoxia to enrich for these neural progenitor cells
prior to further expansion in neurosphere culture.
Method: Adherent cultures of BMSCs (rat/human) were subjected to 1 % oxygen for 24 h and then subcultured as
neurospheres with epidermal growth factor (EGF) and basic fibroblast growth factor supplementation. Neurospheres
and cell progeny were monitored immunocytochemically for marker expression. To generate Schwann cell-like cells,
neurospheres were plated out and exposed to gliogenic medium. The resulting cells were co-cultured with purified
dorsal root ganglia (rat) neurons and then tested for commitment to the Schwann cell fate. Fate-committed Schwann
cells were subjected to in vitro myelination assay.
Results: Transient hypoxic treatment increased the size and number of neurospheres generated from both rat and
human BMSCs. This effect was EGF-dependent and attenuated with the EGF receptor inhibitor erlotinib. Hypoxia did
not affect the capacity of neurospheres to generate neuron- or glia-like precursors. Human Schwann cell-like cells
generated from hypoxia-treated BMSCs demonstrated expression of S100β /p75 and capacity for myelination in vitro.
Conclusion: Enhancing the yield of neural progenitor cells with hypoxic preconditioning of BMSCs in vitro but without
inherent risks of genetic manipulation provides a platform for upscaling production of neural cell derivatives for clinical
application in cell-based therapy.
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Background
Emerging evidence has been provided for the occurrence in
the bone marrow stroma of nestin-expressing neural crest
derivatives critical for the development and maintenance of
the bone marrow niche for hematopoietic stem cells [1–4].
In low-density non-adherent culture, this nestin-expressing
subpopulation formed self-renewing clonal spheres which,
following transfer to adherent culture, could be directed to
differentiate into mesenchymal lineages [5]. Alternatively,
we utilized adherent culture of the sphere cells to direct dif-
ferentiation into Schwann cell-like cells (SCLCs) and then
into fate-committed Schwann cells [6]. By seeding these
bone marrow stromal cell (BMSC)-derived Schwann cells
in a nerve guidance channel that bridged a critical gap in
the severed sciatic nerve of a rat model, we unambiguously
demonstrated the functional capacity of the derived
Schwann cells for remyelination of regrowing axons in the
channel [7]. The proportion of nestin-expressing neural
progenitors in BMSC samples is minimal and is bound to
decline with age [8]. Harvesting BMSCs from donors
involves procedures that are painful, invasive, and time-
consuming. Nevertheless, transplantation of BMSC-
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sourced progenitor cells into animal models of spinal cord
injury yielded dose-dependent improvements in outcome
[9]. This gave impetus to our pursuit of means to enrich for
neural progenitors in the BMSC sample.
Oxygen tension represents a critical component in the
maintenance of the stem/progenitor state. In vivo, neural
stem cells reside in niches where oxygen tension is much
lower than that of ambient air [10]. In vitro, hypoxic con-
ditions promote proliferation and prevent apoptosis of
neural stem/progenitor cells [11] while preserving or en-
hancing their multipotency [12, 13]. Culture of human
neural progenitor cells in increased concentrations of epi-
dermal growth factor (EGF) has a similar effect by increas-
ing cell survival [14]. Correspondingly, upregulation of
EGF receptor (EGFR) was observed among neural stem
cells that had been subjected to hypoxic conditions [12]. It
is unclear how neural progenitor cells located within the
bone marrow niche respond to hypoxia.
We therefore aimed to determine if transient hypoxia
could bring about expansion of the neural progenitor
population in the sampled BMSCs and to find if this effect
was EGF-dependent. As proof-of-principle, attempts were
made to use neural progenitors thus expanded from hu-
man BMSC samples to generate human Schwann cells for
use in cell-based therapy.
Methods
Isolation and culture of rat and human BMSCs
Adult rat BMSCs were prepared with modifications of that
previously described [6, 7]. Briefly, bone marrow was aspi-
rated from femurs of Sprague Dawley rats (200–250 g)
and cultured in BMSC growth medium comprising of
αMEM (Gibco) plus 15 % fetal bovine serum (FBS; Bio-
sera, UK) on tissue culture plates (TPP). Unattached cells
were removed 48 h later and the cultures were maintained
for another 10 to 12 days with medium refreshed every
3 days. BMSCs were detached by incubation in TrypLE
Express (Gibco) at 37 °C for 3 to 5 min and then centri-
fuged at 250 g for 5 min. Cells were resuspended in
growth medium and plated onto new tissue culture plates
at 50,000 cells/cm2. BMSCs were further passaged at a 1:2
ratio when 80 % confluency was attained. The expanded
cells were monitored for immunopositivities of BMSC
markers (CD90, CD73, and STRO-1) and hematopoietic
progenitors (CD45-positive cells) using flow cytometry.
BMSCs within 5 passages which were highly immunoposi-
tive for CD90, CD73, and STRO-1 (>90 %) but generally
immunonegative for CD45 (<1 %), and were used for sub-
sequent experiments.
Human bone marrow samples were obtained from the
Department of Haematology and Bone Marrow Trans-
plantation, Queen Mary Hospital, Hong Kong, from
healthy donors with the study protocols approved by the
Institutional Review Board, The University of Hong Kong
(Study No. UW 10-157). Human BMSC cultures were
established according to Wolfe et al. [15] with modifica-
tions. Briefly, 1 ml of bone marrow aspirate was added to
9 ml αMEM containing 15 % FBS and plated onto tissue
culture plates. Unattached cells were removed 48 h later
and the cultures were maintained for another 10 to 12 days
with medium refreshed every 3 days. BMSCs were de-
tached with TrypLE Express and plated onto new tissue
culture plates at 50,000 cells/cm2. Human BMSCs were
further expanded and monitored for BMSC and
hematopoietic cell markers as mentioned above. Cultures
within 5 passages were used for subsequent experiments.
Hypoxia preconditioning
BMSCs were seeded at 50,000 cells/cm2 and maintained
under normoxic conditions (21 % oxygen) in BMSC
growth medium for up to 16 h. Upon reaching ~80 %
confluence, BMSCs were placed in a hypoxia chamber at
1 % oxygen in BMSC growth medium for 24 h. Control
cultures were maintained under normoxic conditions.
Cell lysates were subjected to Western blot analysis for
hypoxia-inducible factor (HIF)-1-alpha and EGFR, with
β-actin serving as a loading control.
Neurosphere culture
Neural progenitors were enriched from BMSC cultures
as previously described with some modifications [6, 7].
Briefly, rat or human BMSCs from both normoxia and
hypoxia treatment groups were plated onto UltraLow at-
tachment six-well plates (Corning) at a density of 60,000
cells/well in sphere-forming medium comprising
DMEM/F12 supplemented with 2 % B27 (Gibco), basic
fibroblast growth factor (bFGF, 20 ng/ml; Peprotech)
and EGF (Life Technologies). To evaluate the effect of
EGF concentration on neural progenitor enrichment,
three different concentrations (0.2, 20, and 200 ng/ml)
were applied to rat BMSC cultures. The optimal EGF
concentration as determined was subsequently applied
to human BMSC cultures. The culture was maintained
for 12 days with supplements refreshed every 3 days.
Spheres with a diameter ≥50 μm after the enrichment
period were counted and their diameters were assessed
for comparison between the hypoxia and normoxia
groups. For EGFR inhibition assays, sphere-forming
medium containing 7.5 μM erlotinib was used. Spheres
were assessed for abundance of nestin-positive cells.
To confirm that nestin-positive spheres derived from hu-
man BMSCs comprised neural progenitors, the spheres
were plated onto tissue culture plates coated with poly-D-
lysine (PDL, 20 μg/ml; Sigma-Aldrich) and laminin (10 μg/
ml; Roche). Cells were allowed to differentiate in Neuroba-
sal and DMEM/F12 media (1:1, v/v; Life Technologies)
supplemented with 1 % FBS (Biosera). Cultures were main-
tained for 7 days with medium changed every 72 h.
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Cultures were then analyzed immunocytochemically for the
neuronal marker, class III beta-tubulin (Tuj-1) and the
astroglial marker, glial fibrillary acidic protein (GFAP).
Schwann cell derivation and myelin formation
A schematic diagram summarizing the process of generating
fate-committed Schwann cells is illustrated in Additional file
1 (Figure S1). Neurospheres derived from normoxia- and
hypoxia-treated human BMSCs were differentiated into
SCLCs as previously described [6, 7]. Briefly, neurospheres
were plated onto PDL/laminin-coated tissue culture surface
at a density of 10 spheres/cm2. The cultures were main-
tained in glial differentiation medium comprising αMEM
supplemented with β-Her (100 ng/ml; Millipore), bFGF,
PDGF-AA (10 ng/ml and 5 ng/ml, respectively; both from
Peprotech) and 10 % FBS (Biosera, UK) for 7 days with
medium replenished every 2 days. Cells were then moni-
tored immunocytochemically for the Schwann cell markers,
p75 and S100β.
Cultures with >80 % of cells immunopositive for p75
and S100β were regarded as SCLCs; these were cocultured
with purified dorsal root ganglion (DRG) neurons to
achieve commitment to the Schwann cell fate [6]. Briefly,
dissociated DRGs (embryonic day 14-15 rat) were plated
onto PDL/laminin-coated plates and then maintained in
Neurobasal medium supplemented with 2 % B27 and
NGF (10 ng/ml; Covance). Pulse treatment with 5-fluoro-
2'-deoxyuridine and uridine (10 μg/ml each; Sigma-
Aldrich) from days 2 to to 10 was performed to eliminate
endogenous Schwann cells and fibroblasts in DRGs. SCLCs
were then co-cultured with the purified DRG neurons
in glial differentiation medium/neuron maintenance
medium (1:1, v/v) for 2 weeks. By day 15, co-cultures
were passaged to eliminate neurons. Subcultures of
the BMSC-derived Schwann cells remained viable,
showing immunopositivities for p75, S100β and the
human nuclear antigen.
Schwann cells derived from normoxia- and hypoxia-
treated BMSCs in co-culture with purified DRG neurons
were subjected to myelin-forming conditions of DMEM/
F12 and Neurobasal medium (1:1, v/v) supplemented with
2 % B27, 10 ng/ml NGF, and 50 μg/ml vitamin C (Sigma-
Aldrich). The co-cultures were maintained for 15 days
and then monitored immunocytochemically for myelin
basic protein (MBP)-positive segments.
Flow cytometry
All steps were performed at 22 °C unless otherwise speci-
fied. Cells were dissociated from cultures by brief treat-
ment with TrypLE Express (37 °C) and centrifuged at
250 g for 5 min. Cells were fixed using 4 % paraformalde-
hyde (PFA) in phosphate-buffered saline (PBS) for 10 min
and then washed with PBS. Cells were resuspended in
blocking buffer comprising PBS with 3 % v/v normal goat
serum (NGS; Millipore) and 0.01 % v/v Triton X-100
(Sigma-Aldrich) for 30 min. After centrifugation, cells
were incubated with selected primary antibody in blocking
buffer for 2 h. Thereafter, cell pellets were resuspended in
appropriate secondary antibody in blocking buffer for 1 h.
Cells were subjected to flow cytometric analysis with the
use of BD Canto II analyzer. For each marker, at least
10,000 cells were analyzed.
Primary antibodies used were: CD90 (mouse anti-rat/
human, 1:200; BD Bioscience), CD73 (mouse anti-rat/hu-
man, 1:200; BD Bioscience), STRO-1 (mouse anti-rat/hu-
man, 1:50; R&D Systems), CD45 (mouse anti-rat/human,
1:200; BD Bioscience), and nestin (mouse anti-rat/human,
1:200; BD Bioscience). Mouse isotype control (1:200; Life
Technologies) was used in the control experiments. Sec-
ondary antibody used was donkey anti-mouse Alexa 488
(1:500; Life Technologies).
Immunocytochemistry
All steps were performed at 22 °C unless otherwise specified.
Cells were fixed with 4 % PFA in PBS for 10 min and then
rinsed with PBS. The fixed cells were incubated in blocking
buffer comprising PBS with 3 % v/v NGS and 0.1 % v/v
Triton X-100 for 30 min.
Samples were incubated with selected combinations of
primary antibodies overnight at 4 °C followed by approi-
ate combinations of secondary antibodies for 60 min.
Hoechst stain (Sigma-Aldrich) was used to reveal cell
nuclei. In human SCLC/rat DRG co-cultures, nuclei
were labeled with anti-human nuclear antigen (mouse
anti-human, 1:500; Millipore) to ensure that resultant
Schwann cells did not originate from DRG contami-
nants. Images were captured with the use of Olympus
IX71 inverted fluorescence microscope fitted with an
Olympus DP71 camera and Olympus analysis LS Profes-
sional imaging software. For cell counting, 10 random
fields were taken and a minimum of 500 cells were
counted per marker analyzed.
Primary antibodies against class III beta-tubulin (Tuj-1;
mouse anti-rat/human, 1:1000; Covance), p75 (mouse
anti-rat/human, 1:200; Millipore), human nuclei (mouse
anti-human, 1:500; Millipore), S100β (rabbit anti-rat/hu-
man, 1:500; Dako), GFAP (rabbit anti-rat/human, 1:500;
Dako), MBP (mouse anti-human, 1:500; Millipore), and
neurofilament 200 ( NF200,rabbit anti-rat, 1:200; Sigma-
Aldrich) were used. Secondary antibodies used were goat
anti-mouse Alexa 488 and goat anti-rabbit Alexa 594
(1:400 for both; Life Technologies). Mouse and rabbit iso-
type controls (1:200; both Life Technologies) were used in
the control experiments (Additional file 2: Figure S2).
Human BMSCs and NIH/3T3 mouse fibroblast line
were also used as negative controls against the neuronal
marker Tuj1 and glial markers S100β, p75, and GFAP
(Additional file 3: Figure S3).
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Immunoblotting
All steps were performed at 22 °C unless otherwise speci-
fied. Cells were lysed in buffer comprising TrisHCl
(pH 7.4), 1 % Nonidet P-40, 0.25 % sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 μg/ml apro-
tinin, leupeptin, pepstatin, 1 mM Na3VO4, and 1 mM
NaF. Samples were subjected to SDS/PAGE and transfer-
blotted onto PVDF membrane. Membrane was blocked
with 1 % BSA before incubation with the selected primary
antibody at 4 °C overnight. Primary antibodies used were
anti-EGFR (1:1000, mouse-anti rat/human; Santa Cruz)
and anti-HIF1α (mouse anti-rat/human, 1:1000; Gene-
Tex). The membrane was incubated with HRP-conjugated
anti-mouse secondary antibody (Amersham). Bands were
detected with the use of Advansta ECL (Advansta).
Statistics
Student’s t test was used to determine statistically signifi-
cant differences between treatment and control groups.
Statistical significance was accepted at P < 0.05.
Results
Marker profiles of human and rat BMSCs
Adherent cultures of adult human and rat whole bone mar-
row samples were cleared of hematopoietic cells by passage
4. The resulting human BMSCs exhibited bipolar/tripolar
morphology (Fig. 1a) and >90 % of them demonstrated
immunopositivity for the BMSC markers CD90, STRO-1,
and CD73 (Fig. 1b–d, flow cytometry data). Similarly,
>90 % of the resulting rat BMSCs (Additional file 4: Figure
S4A) were immunopositive for CD90, STRO-1, and CD73
(Additional file 4: Figure S4B–D, flow cytometry data). The
neural stem/progenitor marker nestin was immunodetect-
able in approximately 10 % of human (Fig. 1e) and rat
(Additional file 4: Figure S4E) BMSCs. Hardly any (<1 %) of
the human (Fig. 1f) or rat BMSCs (Additional file 4: Figure
S4F) were immunopositive for the hematopoietic progeni-
tor marker CD45. These data indicated that both rat and
human bone marrow cells recoverable by adhesion to tissue
culture plastic were predominantly marrow stromal cells
and that they include a nestin-positive subgroup. The re-
sults are consistent with findings by our group [6] and
others [1, 16].
Hypoxic preconditioning increased EGFR expression in
adult BMSCs
Hypoxia not only induces rapid synthesis of HIF-1α but
also causes cytoplasmic HIF-1α subunits to translocate
to the nucleus where they heterodimerize with HIF-1β
and activate transcription of hypoxia-responsive genes
[17]. As expected, HIF-1α protein levels were increased
in both rat and human BMSCs subjected to hypoxia.
EGFR expression was also increased (Fig. 2a and b). The
increase in expression of both proteins reached
statistical significance in replicates (Fig. 2c and d). Our
results indicated that acute hypoxia was sufficient to up-
regulate the EGFR level in BMSCs.
Hypoxic preconditioning increased the size and number
of neurospheres generated from BMSCs
BMSCs from rats were subjected to neurosphere culture
in medium supplemented with bFGF and EGF. Consistent
with our prior findings [6], resultant spheres consisted of
cells that were largely immunopositive for nestin (Fig. 3a
and b), suggesting the selection and expansion of neural
progenitors in sphere culture. A significant increase in
numbers of neurospheres was observed in hypoxia-treated
BMSCs (Fig. 3c–e). To investigate the effects of EGFR up-
regulation on neurosphere growth, three EGF concentra-
tions (200, 20, and 0.2 ng/ml) were applied to the cultures.
The relative increase in sphere numbers after hypoxia was
found to be highest with the EGF supplement at 0.2 ng/ml
(300 % increase from 16 ± 8 to 50 ± 4 spheres), followed
by 20 ng/ml (90 % increase, from 58 ± 21 spheres to 109 ±
15 spheres), and then 200 ng/ml (45 % increase, from 113
± 13 spheres to 165 ± 12 spheres). Hypoxia also resulted in
an increase in sphere size (Fig. 3f), an effect which was
found to be significant with the EGF supplement at
0.2 ng/ml and 200 ng/ml. Overall, the sphere number and
size increased with the concentration of EGF supplement
in the culture medium. The upregulation of EGFR in re-
sponse to hypoxia suggests that increased sensitivity to-
wards EGF ligands is a potential mechanism.
Ultimately, our aim was to find a means of fostering an
increase of neural progenitors in human BMSC samples for
utility in autologous cell therapy. Within the range of EGF
supplementation tested, 20 ng/ml approximates to that used
in cultures of human neural progenitor cells [18]. We there-
fore utilized this concentration in subsequent neurosphere
enrichment and inhibition studies with human BMSCs.
Again, neurospheres derived from both hypoxia- and
normoxia-treated human BMSCs consisted of cells, 80 % of
which were nestin-positive (Fig. 4a, b, and g). Hypoxia-
treated human BMSCs generated 40 % more spheres than
the normoxic control group (62 ± 4 vs. 87 ± 9 spheres;
Fig. 4c–e). The addition of the EGFR inhibitor erlotinib to
the sphere cultures reduced the numbers of spheres in both
hypoxia- and normoxia-treated cultures (Fig. 4e) while not
significantly affecting sphere size (Fig. 4f). We again infer
that signaling via EGFR is important in determining the
numbers of neurospheres attainable via hypoxic treatment
of BMSCs. However, under our culture conditions, the hyp-
oxic response was still apparent in the presence of erlotinib.
Neurospheres generated following hypoxic
preconditioning contain multipotent neural progenitors
To confirm that neural progenitors enriched from
human BMSCs were multipotent, neurospheres from
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Fig. 1 (See legend on next page.)
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both normoxic and hypoxic treatment groups were
plated onto PDL/laminin-coated culture plates and sub-
jected to culture in low serum concentrations to allow
for differentiation. Both Tuj-1-positive neuron-like cells
showing branching neurites (Fig. 5a and e) and GFAP-
positive glia-like cells showing radial processes (Fig. 5b
and f) could be seen among cells that exited from the
spheres. No significant difference was observed for the
percentage of cells positive for Tuj-1 or GFAP between the
normoxia and hypoxia groups (Fig. 5i). Neurosphere-
derived cells from both normoxic (Fig. 5c and d) and
hypoxic treatment groups (Fig. 5g and h) maintained for
7 days in glial differentiation medium yielded SCLCs,
with >90 % of cells being immunopositive for the Schwann
cell markers p75 and S100β [6, 19]. Again, no significant
differences were observed in the percentage of cells positive
for p75 or S100β between these groups (Fig. 5j). Therefore,
neurospheres generated from human BMSCs following
hypoxia treatment consisted of multipotent progenitors
with differentiation potential towards neuron-like and
glia-like fates, but hypoxia did not bias differentiation
towards either lineage as has been reported [29].
(See figure on previous page.)
Fig. 1 Flow cytometry analysis of human BMSCs. Human BMSCs (a) between passages 5 to 8 were analyzed by flow cytometry. In all panels,
isotype controls are represented by red lines, while immunopositivity for respective cell surface markers are represented by blue lines. Percentages
of positive cells as shown within individual panels are representative of one sample. Human BMSCs were found to be highly immunopositive for
CD90 (b; 93.90 ± 1.77 %), STRO-1 (c; 93.48 ± 2.48 %), and CD73 (d; 91.76 ± 1.30 %). The neural stem/progenitor marker nestin was also found to be
positive in a significant subpopulation of cells (e; 10.31 ± 1.10 %). Hardly any (<1 %) of the cells were immunopositive for the hematopoietic stem
cell marker CD45 (f). Mean ± SD, n = 4
c d
a b
Fig. 2 Acute hypoxia triggers upregulation of hypoxia-inducible factor-1 alpha (HIF-1α) and epidermal growth factor receptor (EGFR) in bone
marrow stromal cells (BMSCs). Western blots of cell lysates for rat (a) and human BMSCs (b) subjected to hypoxia demonstrated increases in HIF-
1α and EGFR protein expression as compared to normoxia controls. c, d Histograms to show densitometric analysis of the indicated protein bands
for human BMSCs. Mean ± SD, n = 3; *p < 0.05
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Myelin-forming Schwann cells can be generated from
hypoxia-treated BMSCs
To test if signaling from rat DRG neurons could drive
human BMSC-derived SCLCs to fate commitment as
we reported for rat BMSC-derived SCLCs [6], the hu-
man BMSC-derived SCLCs were co-cultured with
neurons purified from rat DRG. After 15 days of co-
culture, cells with bi-/tripolar morphology like those
of Schwann cells (Fig. 6a and d) were detectable for
both normoxic and hypoxic treatment groups. Over
90 % of cells were immunopositive for the Schwann
cell markers p75 and S100β, even after withdrawal of
gliogenic factors from the culture medium and
passaging to remove DRG neurons (Fig. 6b, c, e and
f ). Contrary to the transient phenotype that is charac-
teristic of SCLCs, persistence of marker expression
indicates the progress to maturation and fate commit-
ment in the human bone marrow-derived Schwann
cells. As proof-of-principle, the Schwann cells so de-
rived from both treatment groups were further co-
cultured with rat DRG neurons and with ascorbic
acid supplementation to stimulate transition into the
myelination phenotype [20]. Schwann cells derived
from human BMSCs of both treatment groups were
thus shown to generate MBP-positive segments along
the NF200-positive axons of purified DRG neurons
(Fig. 7a–d). Our results support that, subsequent to
hypoxic treatment to increase numbers of neural pro-
genitors in both human and rat BMSC samples, there
is potential to generate myelin-forming Schwann cells.
Discussion
Our results demonstrate that transient exposure of BMSCs
to hypoxia results in increases in the number of spheres
comprising nestin-expressing progenitor cells as expanded
from both rat and human samples. This coincides with
a b
c d
e f
Fig. 3 Hypoxia increases the size and number of neurospheres derived from rat BMSCs in an epidermal growth factor (EGF)-dependent manner.
Representative images of nestin-positive rat BMSC-derived neurospheres formed following normoxia (a, c) and hypoxic preconditioning (b, d)
with EGF supplementation at 20 ng / ml. e Hypoxic preconditioning led to an increase in sphere numbers with EGF concentrations at 200, 20,
and 0.2 ng/ml. f A significant increase in sphere size as compared to the corresponding normoxic control was observed with EGF supplementation at
200 and 0.2 ng/ml. Mean ± SD, n = 4; *p < 0.05, **p < 0.01
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upregulation in EGFR expression among the BMSCs, and
increased sensitivity of the cells to EGF during expansion
of the cells in sphere-forming culture. Given an adherent
substratum and glia-inducing factors in the culture
medium, cells on exit from the sphere cells could be di-
rected to differentiate into SCLCs. Subjecting the SCLCs to
co-culture with DRG neurons committed them to the
Schwann cell fate, as reported for rat cells [6] and shown
here for human cells. With ascorbic acid supplemented
into the co-culture, the potential of the derived Schwann
cells for myelination could be demonstrated in vitro. Our
findings indicate that hypoxic preconditioning of BMSCs in
vitro followed by sphere-forming culture is effective and ef-
ficient for enrichment of neural progenitors in the sample.
This strategy is potentially applicable to neural progenitors
harbored in other tissue samples. These neural progenitors
can represent a source of autologous cells for the purpose
of cell-based therapy in nerve injury, demyelinating disor-
ders, and neurodegenerative diseases.
Cell-based therapy necessitates the isolation of stem/
progenitor cells, a period of in vitro expansion, differenti-
ation of precursors into relevant cell types, and finally
transplantation. The focus of our previous work was on
the directed differentiation of BMSCs into fate-committed
a b
c
e f g
d
Fig. 4 Hypoxia enriches for neural progenitors in human BMSCs. Representative images of human BMSC-derived neurosphere formation following
normoxia (a, c) and hypoxic preconditioning (b, d). Numbers of neurospheres significantly increased in response to hypoxia (e). A reduction in
sphere numbers was observed in both groups with the addition of erlotinib. However, hypoxia-treated human BMSCs yielded significantly more
spheres in the presence of the EGFR inhibitor. Diameter of spheres remained similar irrespective of normoxia/hypoxia preconditioning or
test/control treatment with Erlotinib (f). Numbers of nestin-positive cells within neurospheres were similar amongst both treatment groups (g). Mean
± SD, n = 8 for sphere counting, n = 4 for quantification of nestin-positive cells; *p < 0.05, **p < 0.01
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Schwann cells [6] prior to transplantation in the injured
peripheral [7] and central nervous system [21]. Meta-
analysis of results in animal models of traumatic spinal
cord injury demonstrates that ex vivo differentiation of
stem cells prior to transplantation, as well as increasing
the total numbers of cells transplanted, are pertinent to
improving outcomes [9]. Here, our efforts to enhance clin-
ical utility address the need to expand upon a small pool
of neural precursor cells prior to directed differentiation.
In vivo, the BMSC niche is located amongst perivascular
tissues [3, 5, 8]. Despite being in the vicinity of blood ves-
sels, cells are subject to lowered oxygen tensions and
therefore culture in 21 % oxygen represents a hyperoxic
milieu. In mesenchymal stem cells (MSCs), hypoxia has
indeed been successfully utilized as a means of enhancing
proliferation and multilineage potential for clinical utility,
although variations in cell source and culture condi-
tions have led to differing results [22]. Similar to our
a b
c d
e f
g
i j
h
Fig. 5 Human BMSC-derived neurospheres can generate neuron-like and glia-like cells. Cells that exited from adherent cultures of neurospheres in low-
serum medium differentiated into class III beta-tubulin (Tuj-1) expressing neuron-like cells (a, e) as well as glial fibrillary acidic protein (GFAP)-expressing
glia-like cells (b, f). The Tuj-1- and GFAP-positive fractions did not differ significantly between the normoxia- and hypoxia-treated groups (i). Adherent
cultures of neurospheres in glia-inducing medium fostered differentiation of SCLCs, showing bipolar morphology, and immunopositivity for the Schwann
cell markers p75 (c, g) and S100β (d, h). Numbers of p75- and S100β-positive cells derived from normoxia- and hypoxia-treated BMSCs did not differ (j).
Mean ± SD, n= 4 for neuronal/glial differentiation, n= 3 for SCLC differentiation; *p < 0.05, **p< 0.01. HuNeu human nuclear antigen
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present findings, transplantation of hypoxia-preconditioned
BMSCs into an animal stroke model has enhanced
neurogenesis [23]. Our approach of expanding the
neural progenitors sampled from bone marrow and
the subsequent use of culture conditions to direct dif-
ferentiation into mature neurons and glia has the advan-
tage of being free from genetic reprogramming and the
inherent risks associated with pluripotent stem cell-based
therapies [24]. MSCs that are subject to prolonged hypoxia
exhibit genetic integrity and do not demonstrate tumori-
genicity [25]. We foresee the use of autologous Schwann
cells generated in this manner to be a vital component of
nerve guidance channels, superseding the need to sacrifice
a nerve graft [6, 7]. Furthermore, transplantation of neural
precursors has also progressed to clinical trials; for
example, in amyotrophic lateral sclerosis [26].
When neural precursor cells are isolated and cultured
under hypoxic conditions, an increase in cell prolifera-
tion occurs in combination with a decrease in apoptosis
[11]. Accordingly, our results are compatible with this
previous report as numbers and relative sizes of neu-
rospheres reflect cell turnover. The HIF family of
transcriptional factors are master regulators of the
hypoxic response. In our findings, hypoxia apparently
triggered upregulation of both HIF-1α and EGFR.
Hypoxia-driven proliferation has been attributed to
HIF-1α in embryonic neural progenitors. Alternatively,
marked elevation of EGFR has been reported in neural
progenitors located at the subventricular zone subsequent
to perinatal hypoxia/ischemia [12]. Furthermore, hypoxia
led to elevated expression of heparin-binding EGF [27].
Distinct populations of EGF-responsive and bFGF-
responsive neural precursors exist within the embryonic
telencephalon [28]. Upon reaching maturity, neural stem
cells are ultimately able to proliferate and retain multipo-
tency when cultured in either EGF or bFGF. The presence
of bFGF within the culture medium possibly accounts for
the presence of neurospheres despite EGFR inhibition.
a b c
d e f
g
Fig. 6 Derivation of fate-committed Schwann cells by co-culture of human SCLCs with purified rat DRG neurons. Fate-committed Schwann cells
were generated following 2 weeks of co-culture between human SCLCs and purified rat DRG neurons. These cells were spindle-shaped (a, d), as
well as immunopositive for p75 (b, e) and S100β (c, f). Expression of human nuclear antigen (HuNeu) demonstrates that these Schwann cells were
not contaminated by cells originating from rat DRGs. Numbers of p75- and S100β-immunopositive cells did not show statistical difference when
comparing between normoxic and hypoxic treated groups (g). Mean ± SD, n = 3; *p < 0.05, **p < 0.01
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Our protocol utilizes a period of preconditioning
whereby plated BMSC are subjected to hypoxia prior to
neurosphere culture. Conversely, when adipose tissue-
derived MSCs were cultured under hypoxic conditions
during sphere formation, there was neither change in
sphere size nor number despite an increased predilection
for neurogenesis [29]. It is noteworthy that in glioblast-
oma cells cultured as spheroids, the core already consti-
tutes a hypoxic microenvironment which is able to
induce EGFR upregulation [28]. It is therefore not unex-
pected that hypoxia conferred no additional benefit via
the EGFR/EGF signaling axis when neurospheres as op-
posed to two-dimensional BMSC cultures were exposed
to lowered oxygen tensions.
Conclusion
Hypoxic preconditioning of BMSC samples is a simple
and efficient means of triggering increases in the nestin-
expressing subpopulation of BMSCs prior to expansion
in sphere-forming culture followed by directed differen-
tiation along the neural lineage. As opposed to utilizing
induced pluripotent stem cells (iPSCs) or direct repro-
gramming to differentiated cell types, this approach
avoids genetic manipulation and its associated risks.
Neural precursors and their differentiated cell progeny
generated via this platform can be utilized in autologous
cell therapy. Potentially, hypoxic preconditioning can be
applied to stem/progenitor cells recovered from other
accessible MSC niches such as skin and adipose tissue.
Additional files
Additional file 1: Figure S1. Work flow for the derivation of fate-
committed Schwann cells from BMSCs. BMSCs isolated by means of
adherence to tissue culture plastic were dissociated and maintained for
12 days in the presence of EGF/bFGF on low-attachment culture plates.
Thereafter, resultant neurospheres were plated onto PDL/laminin-coated
culture plates and differentiated into Schwann cell-like cells (SCLCs) in
glial differentiation medium containing β-heregulin, bFGF, and PDGF for
7 days. In order to direct SCLCs to fate commitment, they were co-
cultured with purified and partially dissociated dorsal root ganglia (DRG)
neurons for a further 15 days. (PDF 159 kb)
Additional file 2: Figure S2. Isotype controls for immunocytochemistry.
(A, B) Mouse and rabbit isotype control antibody-stained neurospheres derived
following normoxic and hypoxic treatment, respectively. (C, D) Mouse and
rabbit isotype control antibody-stained SCLCs derived from normoxia- and
hypoxia-treated BMSCs, respectively. (E, F) Mouse and rabbit isotype control
antibody-stained fate-committed Schwann cells generated from normoxia-
and hypoxia-treated BMSCs, respectively. (PDF 211 kb)
Additional file 3: Figure S3. Negative controls for neural marker
immunocytochemistry. Immunocytochemistry performed on 3T3 cells
and human BMSCs as negative controls against the neuronal marker Tuj-
1 (A, B) and glial markers GFAP (C, D), p75 (E, F), and S100β (G, H)
demonstrated an absence of expression. (PDF 478 kb)
Additional file 4: Figure S4. Flow cytometry analysis of rat BMSCs. Rat
BMSCs (A) between passage number 5 and 8 were analyzed by flow
cytometry. In all panels, isotype controls are represented by red lines, while
immunopositivity for respective cell surface markers are represented by blue
lines. Percentages of positive cells as shown within individual panels are
representative of one sample. Immunopositivity for CD90, STRO-1, and
CD73 in isolated rat BMSCs were 95.70 ± 1.21 %, 95.91 ± 1.86 %, and 92.80 ±
1.46 %, respectively (B–D). Immunopositivity for nestin was 11.31 ± 1.25 %
(E). Immunopositivity towards the hematopoietic progenitor marker CD45
was negligible (F). Mean ± SD, n = 4. (PDF 288 kb)
Abbreviations
bFGF: Basic fibroblast growth factor; BMSC: Bone marrow stromal cell;
DRG: Dorsal root ganglion; EGF: Epidermal growth factor; EGFR: Epidermal
growth factor receptor; FBS: Fetal bovine serum; GFAP: Glial fibrillary
acidic protein; HIF: Hypoxia-inducible factor; MBP: Myelin basic protein;
MSC: Mesenchymal stem cell; NGS: Normal goat serum; p75: Low-affinity
nerve growth factor receptor; PBS: Phosphate-buffered saline; PDL: Poly-D-
lysine; PFA: Paraformaldehyde; SCLC: Schwann cell-like cell; Tuj-1: Class III
beta-tubulin
Acknowledgements
We acknowledge Mr. Zhong-Hua Li for his help with fluorescent cell imaging
and Ms. Alice Lui for her help with cell culture.
Funding
This work was supported by the HKU Seed Funding for Basic Science
Research and the Croucher Foundation Scheme for the Development of
Clinical Academics award to GKHS.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article and its supplementary information files.
Authors’ contributions
KLM and YPT contributed equally to this work. Study concept and design:
YPT, KLM, and GKHS. Analysis and acquisition of data: YPT, KLM, and EWYT.
Collection, assembly, and interpretation of data: YPT, KLM, and EWYT. Critical
revision of the manuscript for important intellectual content: KLM, YPT,
EWYT, YSC, DKYS, and GKHS. Study revision and supervision conception:
GKHS. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
a b
Fig. 7 Formation of myelin basic protein (MBP)-positive myelin
segments by human BMSC-derived Schwann cells. Schwann cells
derived from normoxic (a) and hypoxic treatment groups (b)
formed MBP-positive myelin segments along NF200-expressing
axons of DRG neurons. Individual myelin segments are indicated
in enlarged images (a*, b*)
Mung et al. Stem Cell Research & Therapy  (2016) 7:146 Page 11 of 12
Consent for publication
Bone marrow donors gave their written consent for data generated from
their cells to be utilized in scientific studies. No personal details were
disclosed in this publication.
Ethics approval and consent to participate
Human BMSCs were obtained from the bone marrow aspirate of healthy
donors from which informed consent had been obtained. The study
protocol was approved by the Institutional Review Board, The University of
Hong Kong (Study No. UW 10-157).
Author details
1Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of
Medicine, The University of Hong Kong, Pokfulam, Hong Kong. 2School of
Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong
Kong, Pokfulam, Hong Kong. 3General Office, 5/F, Professorial Block, Queen
Mary Hospital, Pokfulam, Hong Kong.
Received: 30 June 2016 Revised: 25 August 2016
Accepted: 6 September 2016
References
1. Takashima Y, Era T, Nakao K, Kondo S, Kasuga M, Smith AG, Nishikawa S.
Neuroepithelial cells supply an initial transient wave of MSC differentiation.
Cell. 2007;129:1377–88.
2. Morikawa S, Mabuchi Y, Niibe K, Suzuki S, Nagoshi N, Sunabori T, Shimmura S,
Nagai Y, Nakagawa T, Okano H, Matsuzaki Y. Development of mesenchymal
stem cells partially originate from the neural crest. Biochem Biophys Res
Commun. 2009;379:1114–9.
3. Yamazaki S, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, Taketo
MM, Karlsson S, Iwama A, Nakauchi H. Nonmyelinating Schwann cells
maintain hematopoietic stem cell hibernation in the bone marrow niche.
Cell. 2011;147:1146–58.
4. Isern J, Garcia-Garcia A, Martin AM, Arranz L, Martin-Perez D, Torroja C, Sanchez-
Cabo F, Mendez-Ferrer S. The neural crest is a source of mesenchymal stem cells
with specialized hematopoietic stem cell niche function. Elife. 2014;3:e03696.
5. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira
SA, Scadden DT, Ma’ayan A, Enikolopov GN, Frenette PS. Mesenchymal and
haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;
466:829–34.
6. Shea GK, Tsui AY, Chan YS, Shum DK. Bone marrow-derived Schwann cells
achieve fate commitment—a prerequisite for remyelination therapy. Exp
Neurol. 2010;224:448–58.
7. Ao Q, Fung CK, Tsui AY, Cai S, Zuo HC, Chan YS, Shum DK. The regeneration
of transected sciatic nerves of adult rats using chitosan nerve conduits
seeded with bone marrow stromal cell-derived Schwann cells. Biomaterials.
2011;32:787–96.
8. Nagoshi N, Shibata S, Kubota Y, Nakamura M, Nagai Y, Satoh E, Morikawa S,
Okada Y, Mabuchi Y, Katoh H, Okada S, Fukuda K, Suda T, Matsuzaki Y,
Toyama Y, Okano H. Ontogeny and multipotency of neural crest-derived
stem cells in mouse bone marrow, dorsal root ganglia, and whisker pad.
Cell Stem Cell. 2008;2:392–403.
9. Antonic A, Sena ES, Lees JS, Wills TE, Skeers P, Batchelor PE, Macleod MR, Howells
DW. Stem cell transplantation in traumatic spinal cord injury: a systematic review
and meta-analysis of animal studies. PLoS Biol. 2013;11:e1001738.
10. Erecinska M, Silver IA. Tissue oxygen tension and brain sensitivity to
hypoxia. Respir Physiol. 2001;128:263–76.
11. Studer L, Csete M, Lee SH, Kabbani N, Walikonis J, Wold B, McKay R.
Enhanced proliferation, survival, and dopaminergic differentiation of CNS
precursors in lowered oxygen. J Neurosci. 2000;20:7377–83.
12. Felling RJ, Snyder MJ, Romanko MJ, Rothstein RP, Ziegler AN, Yang Z,
Givogri MI, Bongarzone ER, Levison SW. Neural stem/progenitor cells
participate in the regenerative response to perinatal hypoxia/ischemia. J
Neurosci. 2006;26:4359–69.
13. Santilli G, Lamorte G, Carlessi L, Ferrari D, Rota Nodari L, Binda E, Delia D, Vescovi
AL, De Filippis L. Mild hypoxia enhances proliferation and multipotency of
human neural stem cells. PLoS One. 2010;5:e8575.
14. Nelson AD, Suzuki M, Svendsen CN. A high concentration of epidermal
growth factor increases the growth and survival of neurogenic radial glial
cells within human neurosphere cultures. Stem Cells. 2008;26:348–55.
15. Wolfe M, Pochampally R, Swaney W, Reger RL. Isolation and culture of bone
marrow-derived human multipotent stromal cells (hMSCs). Methods Mol
Biol. 2008;449:3–25.
16. Wislet-Gendebien S, Hans G, Leprince P, Rigo JM, Moonen G, Rogister B.
Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to
excitable neuron-like phenotype. Stem Cells. 2005;23:392–402.
17. Vaupel P. The role of hypoxia-induced factors in tumor progression.
Oncologist. 2004;9 Suppl 5:10–7.
18. Joh T, Itoh M, Katsumi K, Yokoyama Y, Takeuchi T, Kato T, Wada Y, Tanaka R.
Physiological concentrations of human epidermal growth factor in
biological fluids: use of a sensitive enzyme immunoassay. Clin Chim Acta.
1986;158:81–90.
19. Wang W, Itoh S, Konno K, Kikkawa T, Ichinose S, Sakai K, Ohkuma T, Watabe K.
Effects of Schwann cell alignment along the oriented electrospun chitosan
nanofibers on nerve regeneration. J Biomed Mater Res A. 2009;91:994–1005.
20. Eldridge CF, Bunge MB, Bunge RP. Differentiation of axon-related Schwann
cells in vitro: II. Control of myelin formation by basal lamina. J Neurosci.
1989;9:625–38.
21. Chau CH, Shum DK, Li H, Pei J, Lui YY, Wirthlin L, Chan YS, Xu XM.
Chondroitinase ABC enhances axonal regrowth through Schwann cell-
seeded guidance channels after spinal cord injury. FASEB J. 2004;18:194–6.
22. Das R, Jahr H, van Osch GJ, Farrell E. The role of hypoxia in bone marrow-
derived mesenchymal stem cells: considerations for regenerative medicine
approaches. Tissue Eng Part B Rev. 2010;16:159–68.
23. Wei L, Fraser JL, Lu ZY, Hu X, Yu SP. Transplantation of hypoxia preconditioned
bone marrow mesenchymal stem cells enhances angiogenesis and
neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012;46:635–45.
24. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical
hurdle for pluripotent stem cell therapies. Nat Med. 2013;19:998–1004.
25. Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH, Hung SC. Hypoxia
inhibits senescence and maintains mesenchymal stem cell properties
through down-regulation of E2A-p21 by HIF-TWIST. Blood. 2011;117:459–69.
26. Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, Polak M,
Bordeau J, Sakowski SA, Glass JD. Intraspinal neural stem cell transplantation
in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;
75:363–73.
27. Tanaka N, Sasahara M, Ohno M, Higashiyama S, Hayase Y, Shimada M. Heparin-
binding epidermal growth factor-like growth factor mRNA expression in
neonatal rat brain with hypoxic/ischemic injury. Brain Res. 1999;827:130–8.
28. Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der Kooy D.
Distinct neural stem cells proliferate in response to EGF and FGF in the
developing mouse telencephalon. Dev Biol. 1999;208:166–88.
29. Chung DJ, Wong A, Hayashi K, Yellowley CE. Effect of hypoxia on generation of
neurospheres from adipose tissue-derived canine mesenchymal stromal cells.
Vet J. 2014;199:123–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mung et al. Stem Cell Research & Therapy  (2016) 7:146 Page 12 of 12
